Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women
Objective: To determine the levels of S-RBD antibodies in premenopausal and postmenopausal women who received the COVID-19 vaccine. Methods: This study involved 21 premenopausal and postmenopausal women who received two doses of CoronaVac at 28 days intervals. The duration of vaccination was 4-24...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Indonesian Society of Obstetrics and Gynecology
2023-02-01
|
| Series: | Indonesian Journal of Obstetrics and Gynecology |
| Online Access: | https://inajog.com/index.php/journal/article/view/1666 |
| _version_ | 1827931869422813184 |
|---|---|
| author | Juminten Saimin Irawaty Irawaty Nur Indah Purnamasari Yenti Purnamasari Sufiah Asri Mulyawati |
| author_facet | Juminten Saimin Irawaty Irawaty Nur Indah Purnamasari Yenti Purnamasari Sufiah Asri Mulyawati |
| author_sort | Juminten Saimin |
| collection | DOAJ |
| description | Objective: To determine the levels of S-RBD antibodies in premenopausal and postmenopausal women who received the COVID-19 vaccine.
Methods: This study involved 21 premenopausal and postmenopausal women who received two doses of CoronaVac at 28 days intervals. The duration of vaccination was 4-24 weeks. This study was conducted on May–October 2021 in Kendari City, Indonesia. Blood samples were taken at a health care facility and examined at the Prodia Clinical Laboratory. Participants were healthy women, willing to participate, and signed informed consent. Participants were excluded if they had a history of COVID-19, had taken antibiotics or immunomodulators in the last 24 hours, had a history of acute/chronic inflammatory disease and malignancy, were traumatized and received monoclonal antibody therapy.
Results: Participants were 52.95±7.61 years old. The duration of the second vaccination was 13.67±5.26 weeks. The lowest level of S-RBD antibody was menopause with vaccination duration <=12 weeks (185.59±112.34 U/mL), and the highest was premenopause with vaccination duration >12 weeks (257.5±3.54 U/mL). The S-RBD antibody level in premenopausal women was higher than in menopausal women at the duration of vaccination <=12 weeks (223.37±63.45 vs 185.59±112.34 U/mL) and >12 weeks (257.5±3.54 vs. 225.55±91.14 U/mL). There was no significant difference in S-RBD antibody levels between two or more groups (p>0.05).
Conclusion: S-RBD antibody levels in postmenopausal women after receiving two doses of COVID-19 vaccine were lower than in premenopausal women, but the difference was not significant. S-RBD antibody levels in postmenopausal women increased with increasing duration of vaccine administration.
Keywords: menopause, immune response, COVID-19 vaccine, S-RBD antibody |
| first_indexed | 2024-03-13T07:00:05Z |
| format | Article |
| id | doaj.art-66535ab1a8c5444cb52b8fae40208b02 |
| institution | Directory Open Access Journal |
| issn | 2338-6401 2338-7335 |
| language | English |
| last_indexed | 2024-03-13T07:00:05Z |
| publishDate | 2023-02-01 |
| publisher | Indonesian Society of Obstetrics and Gynecology |
| record_format | Article |
| series | Indonesian Journal of Obstetrics and Gynecology |
| spelling | doaj.art-66535ab1a8c5444cb52b8fae40208b022023-06-07T03:31:32ZengIndonesian Society of Obstetrics and GynecologyIndonesian Journal of Obstetrics and Gynecology2338-64012338-73352023-02-017810.32771/inajog.v11i1.16661666Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal WomenJuminten Saimin0Irawaty Irawaty1Nur Indah Purnamasari2Yenti Purnamasari3Sufiah Asri Mulyawati4Faculty of Medicine Halu Oleo University KendariUniversitas Halu OleoUniversitas Halu OleoUniversitas Halu OleoUniversitas Halu OleoObjective: To determine the levels of S-RBD antibodies in premenopausal and postmenopausal women who received the COVID-19 vaccine. Methods: This study involved 21 premenopausal and postmenopausal women who received two doses of CoronaVac at 28 days intervals. The duration of vaccination was 4-24 weeks. This study was conducted on May–October 2021 in Kendari City, Indonesia. Blood samples were taken at a health care facility and examined at the Prodia Clinical Laboratory. Participants were healthy women, willing to participate, and signed informed consent. Participants were excluded if they had a history of COVID-19, had taken antibiotics or immunomodulators in the last 24 hours, had a history of acute/chronic inflammatory disease and malignancy, were traumatized and received monoclonal antibody therapy. Results: Participants were 52.95±7.61 years old. The duration of the second vaccination was 13.67±5.26 weeks. The lowest level of S-RBD antibody was menopause with vaccination duration <=12 weeks (185.59±112.34 U/mL), and the highest was premenopause with vaccination duration >12 weeks (257.5±3.54 U/mL). The S-RBD antibody level in premenopausal women was higher than in menopausal women at the duration of vaccination <=12 weeks (223.37±63.45 vs 185.59±112.34 U/mL) and >12 weeks (257.5±3.54 vs. 225.55±91.14 U/mL). There was no significant difference in S-RBD antibody levels between two or more groups (p>0.05). Conclusion: S-RBD antibody levels in postmenopausal women after receiving two doses of COVID-19 vaccine were lower than in premenopausal women, but the difference was not significant. S-RBD antibody levels in postmenopausal women increased with increasing duration of vaccine administration. Keywords: menopause, immune response, COVID-19 vaccine, S-RBD antibodyhttps://inajog.com/index.php/journal/article/view/1666 |
| spellingShingle | Juminten Saimin Irawaty Irawaty Nur Indah Purnamasari Yenti Purnamasari Sufiah Asri Mulyawati Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women Indonesian Journal of Obstetrics and Gynecology |
| title | Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women |
| title_full | Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women |
| title_fullStr | Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women |
| title_full_unstemmed | Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women |
| title_short | Overview of S-RBD Antibody Levels After Covid-19 Vaccination in Premenopausal and Menopausal Women |
| title_sort | overview of s rbd antibody levels after covid 19 vaccination in premenopausal and menopausal women |
| url | https://inajog.com/index.php/journal/article/view/1666 |
| work_keys_str_mv | AT jumintensaimin overviewofsrbdantibodylevelsaftercovid19vaccinationinpremenopausalandmenopausalwomen AT irawatyirawaty overviewofsrbdantibodylevelsaftercovid19vaccinationinpremenopausalandmenopausalwomen AT nurindahpurnamasari overviewofsrbdantibodylevelsaftercovid19vaccinationinpremenopausalandmenopausalwomen AT yentipurnamasari overviewofsrbdantibodylevelsaftercovid19vaccinationinpremenopausalandmenopausalwomen AT sufiahasrimulyawati overviewofsrbdantibodylevelsaftercovid19vaccinationinpremenopausalandmenopausalwomen |